Can we give it another chance? Salvage treatments for recurring prostate cancer
Poster Session 58

Sunday 19 July 15:45 - 17:15

**Location:** Yellow Area, Room Forum

**Chairs:** To be confirmed
S. Joniau, Leuven (BE)
A. Lamb, Oxford (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

**796**
Validation and implementation of a mobile app decision support system for quality assurance of tumor boards. Analyzing the concordance rates for prostate cancer at a multidisciplinary tumor board of a tertiary referral centre
To be confirmed

**797**
Patient and region based accuracy of PSMA PET/CT in patients undergoing salvage lymphadenectomy for lymph node recurrence following primary treatment
To be confirmed

**798**
What is the optimal surgical template for salvage pelvic lymph node dissection in patients with pelvic lymph-node recurrent prostate cancer? Results from a large, multi-institutional series
To be confirmed

**799**
Robotic salvage lymph node dissection in prostate cancer: Lessons learned from 50 cases and implications for future clinical management
To be confirmed

**800**
Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial
To be confirmed

**801**
PSMA PET/CT to guide salvage treatment post prostatectomy: The IMPPORT trial
To be confirmed

**802**
Salvage therapies for PSMA PET-positive nodal recurrent prostate cancer
To be confirmed

**803**
Metastasis-directed therapy for oligorecurrent prostate cancer: Oncological outcomes of a tertiary referral centre
To be confirmed

**804**
Local recurrence after radical prostatectomy and additive radiation – can PSMA-radioguided surgery prolong therapy-free survival?
To be confirmed

**805**
Refining patient selection for salvage radical prostatectomy: Oncological outcomes compared between EAU guidelines-compliant and non-compliant patients
To be confirmed
<table>
<thead>
<tr>
<th></th>
<th>Title</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>806</td>
<td>Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter study</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>807</td>
<td>Salvage pelvic mass resection of locally recurrent prostate cancer delays the need for systemic interventions</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>808</td>
<td>Feasibility and oncologic outcome of salvage surgery in isolated seminal vesical remnants after radical prostatectomy</td>
<td>To be confirmed</td>
</tr>
<tr>
<td>809</td>
<td>A cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer</td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>